

The Global Attack Against Bacteria's Defensive Walls  
SMi's is Proud to Present: Superbugs & Superdrugs USA  
November 14th & 15th 2016  
Renaissance Woodbridge Hotel, Iselin, New Jersey  
[www.superbugs-usa.com/inderscience](http://www.superbugs-usa.com/inderscience)

---

Broadening horizons on the growing global threat of Antimicrobial resistance (AMR) for almost two decades at the sell-out Superbugs & Superdrugs conference in Europe, SMi is thrilled to announce the expansion of its antimicrobial portfolio of events across the Atlantic with the release of Superbugs & Superdrugs USA. This year's show in Iselin, New Jersey, will play host to an audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to discuss the latest clinical advancements and funding opportunities.

With huge interest from leaders in the field including pending confirmations from PAHO/WHO, Astra Zeneca and other senior industry representatives, we have worked closely with an expert panel of speakers to present an agenda that is shaping up to be the best Superbugs & Superdrugs event to date.

The programme will hone in on key topics such as public private partnerships, collaboration, R&D, scientific priorities for antibiotic discovery, novel antibacterial therapeutic approaches, antibiotic stewardship, rapid diagnostic tools, combination therapies, resistance prevention, plus much more!

Featured speakers include:

- Dr Christopher Houchens, Branch Chief, Antibacterial's Program, BARDA
- Dr Rosemarie Aurigemma, Chief, Biodefense Drug Development Section , NIH
- Dr Anthony Simon Lynch, Senior Scientific Director, Janssen Research & Development LLC
- Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, Pfizer
- Dr Alita Miller, Director of Biology, Entasis Therapeutics
- William J Weiss, Director, Pre-Clinical Services, UNT Health Science Center
- Dr Domingo Gargallo-Viola, Co-Founder and CSO, ABAC Therapeutics
- Dr David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd

Reasons to join:

- Network with industry-leading experts on drug and antimicrobial material developments
- Learn new funding opportunities from BARDA and US National plans, to combat antimicrobial resistance
- Strengthen your antibiotic pipeline with new insights on microbiome profiling to fight multi-resistant gram negative infections
- Hear important discussions on tackling major bottlenecks that hinder development of new antimicrobial drugs with our star panel line-up

- Discover novel protein-based biologics for the treatment and prevention of serious bacterial infections from Janssen

Attendee Testimonials From Our Recent Superbugs Show In London:

- “Great meeting to network and have time to discuss face to face. Key questions and issues. Very collaborative open meeting.” – Roche
- “It was one of the most useful scientific conferences that I have attended” – BARDA
- “Good mix of problems such as funding and novel opportunities and success stories” – TNO
- “I enjoyed attending the meeting this year and wanted to thank you for your efforts in organizing it” – UNT Health Science Centre
- “I like the mix of early stage technologies and also later stage products being presented” – Sempra Pharmaceuticals

Register early to take advantage of early bird savings at [www.superbugs-usa.com/inderscience](http://www.superbugs-usa.com/inderscience) or contact Teri Arri on email: [tarri@smi-online.co.uk](mailto:tarri@smi-online.co.uk), tel: +44 (0)20 7827 6162